EA9181 trial: what clinicians have said so far
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
- NCT04530565 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on EA9181 (blinatumomab plus dasatinib; blinatumomab plus ponatinib in newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia in adults) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EA9181 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 5 posts on X, typically up to 22 once built | |
| 1 YouTube video, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Interventions
- Biospecimen Collection; Blinatumomab; Bone Marrow Aspiration and Biopsy; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin Hydrochloride; Echocardiography Test; Electrocardiography; Lumbar Puncture; Mesna; Methotrexate; Multigated Acquisition Scan; Ponatinib Hydrochloride; Prednisone; Vincristine Sulfate
- Arms
- Arm A (steroid, TKI), Single Arm Pre-Induction · Active comparator
- Arm B (steroid, TKI, chemotherapy) · Experimental
- Arm C (steroid, TKI, chemotherapy, immunotherapy) · Experimental
- Arm D (steroid, TKI, chemotherapy, immunotherapy) · Experimental
- Arm E (steroid, TKI, chemotherapy) · Experimental
- Enrollment
- 348 (estimated)
- Primary outcomes
- Overall survival (OS)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Jan 25, 2021
- Primary completion
- Jul 1, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT04530565 · updated Nov 12, 2026
Publications
linked from the registry- Davis KL, Yao CC, Zimmerman JAO, Rau RE. Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2025 Dec;23(12):e257067. doi: 10.6004/jnccn.2025.7067. PubMed 41671463